Latest Breaking News On - Apexigen inc - Page 1 : comparemela.com

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s.

United statesLaras sullivanPamela connealyApexigen incCompany annual report on formPyxis oncology incExchange commissionAntibody drug conjugatePyxis oncologyPrivate securities litigation reform actAnnual report

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 : Phase 1 trial now focusing on NSCLC and other tumor types; data expected 2H 2024. Cash runway.

United statesPam connealyLaras sullivanApexigen incCompany quarterly report on formPyxis oncology incChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPam connealyLaras sullivanApexigen incPyxis oncology incCompany quarterly report on formOncology announces initiativesPrioritize leadReports financial resultsProvides corporateChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07.11.2023 - PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024. PYX-106 (a fully human immunotherapy .

United statesPam connealyLaras sullivanCompany quarterly report on formApexigen incPyxis oncology incChief executive officerPyxis oncologyPrivate securities litigation reform actQuarterly reportConsolidated statements

Invivyd Appoints William Duke as Chief Financial Officer

WALTHAM, Mass., Sept. 05, 2023 Invivyd, Inc. , a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the.

Scott youngWilliam dukeDave heringGabriella linville englerBusiness administrationPyxis oncology incBentley collegeValeritas incPulmatrix incApexigen incInvivyd incStonehill collegeKaleido biosciences incGenzyme corporationExchange commissionChief financial